Historic Real-World Outcomes and Future Benchmarks for Patients with Diffuse Large B-Cell Lymphoma Receiving First- and Second-Line Therapy in Austria – a Large Single-Center Experience
Michael Leisch(Paracelsus Medical University), Thomas Melchardt(Paracelsus Medical University), Dominik Kiem(Paracelsus Medical University), Bernd Schöpf(Innsbruck Medical University), Mayer Marie-Christina(Paracelsus Medical University), Gianfranco Pocobelli(Cancer Research Institute of the Slovak Academy of Sciences), Anton Kugler(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), Christoph Grabmer(Paracelsus Medical University)
Cited by 0
Related Papers
Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas
|International Journal of Mass Spectrometry|2007|276
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
|Blood|2015|186
OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation
|Nature Communications|2020|139
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia
|Cancer|2010|65
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b
|American Journal of Hematology|2014|54